Your Health, We Care
News, as an important means of information dissemination, covers a variety of fields and aspects, It is of great significance for transmitting information, establishing an image, and promoting development. Here, we will introduce in detail the three sections company news, medicine news, and research news.
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued favorable opinions, proposing an amendment to the mark···【more】
Article source: Captain MedicineRelease date: 2025-01-13Recommended: 157
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced solid tumors, although further prospective research is still required. Historica···【more】
Article source: Captain MedicineRelease date: 2025-01-06Recommended: 155
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administration (FDA) has given the green light to the first generic version of Victoza (···【more】
Article source: Captain MedicineRelease date: 2024-12-30Recommended: 170
The new indication involves the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer with tumors with EGFR exon 19 deletion or exon 21 (L858R)···【more】
Article source: Captain MedicineRelease date: 2024-12-24Recommended: 160
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combination with glucocorticoids (steroids) to help manage androgen (testosterone-like ···【more】
Article source: Captain MedicineRelease date: 2024-12-17Recommended: 145
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, obecabtagene autoleucel, demonstrated a high res···【more】
Article source: Captain MedicineRelease date: 2024-12-13Recommended: 105
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) gave a positive recommendation for the approval of toripalimab (brand name Lo···【more】
Article source: Captain MedicineRelease date: 2024-08-26Recommended: 247
On June 27, 2024, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use issued a favorable opinion recommending the approval of a marketing autho···【more】
Article source: Captain MedicineRelease date: 2024-08-19Recommended: 191
On August 2, 2024, the FDA granted accelerated approval to afamitresgene autoleucel, marking the first gene-engineered T-cell therapy approved for the treatment of solid tumors. Th···【more】
Article source: Captain MedicineRelease date: 2024-08-12Recommended: 206
On June 14, 2024, the US Food and Drug Administration (FDA) granted approval for blinatumomab (Blincyto, Amgen Inc.) to be used in the consolidation phase of multiphase chemotherap···【more】
Article source: Captain MedicineRelease date: 2024-08-07Recommended: 206
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. For patients with advanced or metastatic NSCLC, partic···【more】
Article source: Captain MedicineRelease date: 2024-08-05Recommended: 242
On June 26, 2024, the Food and Drug Administration (FDA) granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.), a bispecific CD20-directed CD3 T-cell engager,···【more】
Article source: Captain MedicineRelease date: 2024-08-01Recommended: 195
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended：1572025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended：1552025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended：1702024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended：1602024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended：1452024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended：1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended：2472024-26-08
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
